🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Cohort Study on the Efficacy of Bariatric Surgery for Rapidly Progressing Diabetic Nephropathy

Recruitingn/aAges 18 Years - 65 YearsAllChina-Japan Friendship Hospital
NCT06661174 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Establish a cohort of diabetic kidney disease(DKD) patients with intensive weight loss treatment to evaluate the impact of intensive weight loss treatment on the renal prognosis of DKD and construct a prediction model for the improvement of renal outcomes after weight loss.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age 18 to 65 years old; * BMI\>25Kg/m2 or abdominal obesity (i.e. waist circumference\>90cm for men and\>85cm for women); * eGFR\<30ml/min/1.73m2 or urinary microalbumin≥300mg/g, eGFR\<60ml/min/1.73m2. Exclusion Criteria: * Patients who are taking glucocorticoids; * Combined with tumors; ③Combined with autoimmune diseases; ④Serum albumin\<25g/L.
💊

What it tests

  • Bariatric surgery
  • Non-surgical therapy
📍

Where

1 site
China-Japan Friendship Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy